The effect of estrogen and progesterone therapy on perimenopausal uterine fibroids
Objective To analyze the effect of estrogen and progesterone therapy on perimenopausal uterine fibroids.Method 132 patients with perimenopausal uterine fibroids who visited the First People's Hospital of Tonglu County,Hangzhou City,Zhejiang Province from January 2022 to December 2022 were selected.According to the random number table method,they were divided into a conventional treatment group and an estrogen and progesterone group,with 66 cases in each group.The conventional treatment group was given oral administration of sitagliptin at a dose of 20mg,twice a day;Vi-tamin Bl orally,20mg,twice a day,treatment for 3 months;The estrogen and progesterone group was treated with estrogen and progesterone in addition to the conventional treatment group.Estradiol valerate was orally administered at a dose of 0.5mg,once a day,for 3 consecutive weeks.From day 12 to 14,dexamethasone was administered at a dose of 5mg,once a day,until the end of the 3-month treatment period.Afterwards,the dosage of E2 should be adjusted based on the patient's perimenopausal symptoms,estradiol(E2)levels,and combined with the minimum effective dose recommended by the menopausal study group of the Chinese Medical Association,as well as the individual condition of the patient.The maximum dose should not exceed 1.5mg/d.Observe the size of uterine fibroids and endometrial thickness,serum gonadal axis related hormone indi-cators[estradiol(E2),follicle stimulating hormone(FSH),luteinizing hormone(LH)],perimenopausal symptoms(hot flashes,night sweats,palpitations,insomnia score),Kupperman score,and quality of life score before and after treatment in two groups.Results(1)After treatment,there was no significant change in the size of uterine fibroids and endometrial thick-ness between the two groups compared to before treatment,and there was no statistically significant difference between the groups(P＞0.05).(2)After treatment,the serum E2 levels in both groups increased(P＜0.05),while the serum FSH and LH levels decreased(P＜0.05).The serum E2 levels in the estrogen and progesterone group were higher than those in the conven-tional treatment group(P＜0.05),and the serum FSH and LH levels were lower than those in the conventional treatment group(P＜0.05).(3)After treatment,the scores of hot flashes,night sweats,palpitations,and insomnia in both groups decreased(P＜0.05),and the scores of hot flashes,night sweats,palpitations,and insomnia in the estrogen and progesterone group were low-er than those in the conventional treatment group(P＜0.05).(4)After treatment,both groups showed a significant decrease in Kupperman scores(P＜0.05)and a significant increase in quality of life scores(P＜0.05).In addition,the Kupperman scores of the estrogen and progesterone group were lower than those of the conventional treatment group(P＜0.05),and the quality of life scores were higher than those of the conventional treatment group(P＜0.05).Conclusion Low dose estrogen and proges-terone treatment for perimenopausal uterine fibroids can regulate the secretion function of the patient's gonadal axis,improve perimenopausal symptoms,and have no significant effect on uterine fibroids.
uterine fibroidsperimenopausal periodestrogengonadal axis secretion functionquality of life
万方数据
维普
